Literature DB >> 7776988

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

S C Cannegieter1, F R Rosendaal, A R Wintzen, F J van der Meer, J P Vandenbroucke, E Briët.   

Abstract

BACKGROUND: The optimal intensity of oral anticoagulant therapy for patients with mechanical heart valves (i.e., the level at which thromboembolic complications are effectively prevented without excessive bleeding) is not known. We attempted to determine the optimal intensity by calculating the incidence of both complications at different levels of anticoagulation.
METHODS: Data were collected on all patients with mechanical heart valves who have been seen at four regional Dutch anticoagulation clinics since 1985. The primary outcome events were episodes of thromboembolism or major bleeding. The intensity-specific incidence of each type of event was calculated as the number of events that occurred at a certain intensity of anticoagulation (expressed in terms of the international normalized ratio [INR]) divided by the number of patient-years during which the INR was at this level in the total patient population.
RESULTS: A total of 1608 patients were followed during 6475 patient-years. Cerebral embolism occurred in 43 patients (0.68 per 100 patient-years) and peripheral embolism in 2 (0.03 per 100 patient-years). Intracranial and spinal bleeding occurred in 36 patients (0.57 per 100 patient-years) and major extracranial bleeding in 128 (2.1 per 100 patient-years). The optimal intensity of anticoagulation, at which the incidence of both complications was lowest, was achieved when the INR was between 2.5 and 4.9.
CONCLUSIONS: The intensity of anticoagulant therapy for patients with prosthetic heart valves is optimal when the INR is between 2.5 and 4.9. To achieve this level of anticoagulation, a target INR of 3.0 to 4.0 is recommended.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776988     DOI: 10.1056/NEJM199507063330103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  154 in total

Review 1.  Out-of-hospital coagulation monitoring and management.

Authors:  J E Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

Review 3.  Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery.

Authors:  C Gohlke-Bärwolf
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

Review 4.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

5.  Bleeding incidence after oral surgery with continued oral anticoagulation.

Authors:  Wolfgang Eichhorn; Jens Burkert; Oliver Vorwig; Marco Blessmann; Georg Cachovan; Jürgen Zeuch; Marc Eichhorn; Max Heiland
Journal:  Clin Oral Investig       Date:  2011-12-13       Impact factor: 3.573

Review 6.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

7.  Ischemic Stroke Prevention.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 8.  Guidelines for stroke prevention in patients with atrial fibrillation.

Authors:  P A Howard
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

9.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

10.  Interactions between cardiovascular and cerebrovascular disease.

Authors:  Giuseppe Di Pasquale; Stefano Urbinati; Enrica Perugini; Simona Gambetti
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.